**Current Price and Recent Performance**
- As of the latest available data, Max Healthcare Institute Ltd (MAXHEALTH) is trading around ₹1,084.40, showing a 0.64% increase in the past 24 hours
- The stock hit a high of ₹1,095.00 and a low of ₹1,066.50 in the most recent trading session, with an average traded price of ₹1,075.13
- Over the past week, the stock is down by 0.97%, but it has risen 8.23% over the past month and 30.78% over the last year
**Historical Price Levels**
- MAXHEALTH reached its all-time high of ₹1,227.95 on January 8, 2025
- The all-time low was ₹97.15, recorded on November 12, 2020
**Analyst Forecasts and Valuation**
- Analyst price targets range from a minimum of ₹615.00 to a maximum of ₹1,390.00
- The stock is trading at a price-to-earnings (PE) ratio of 100.12 and a price-to-book (PB) ratio of 12.59, which is higher than the sector averages (sector PE: 47.87, sector PB: 6.12)
- Dividend yield is low at 0.14%
**Technical and Volatility Insights**
- MAXHEALTH is 2.61 times as volatile as the Nifty index, indicating higher price swings.
- The 50-day moving average (DMA) is at ₹1,062, suggesting the current price is above this technical support level.
MAXHEALTH's valuation is high compared to peers, reflecting strong investor expectations
**Fundamental Performance**
- Revenue has grown at a compound annual rate of 27.47% over the last five years, outpacing the industry average of 10.01%
- Net profit for FY 2023-24 was ₹687 crore, with a slight decline of 1.02% compared to the previous year, despite a 22.93% rise in revenue.
- Promoter and institutional holdings have remained stable in recent quarters
**Summary**
MAXHEALTH has demonstrated robust long-term price appreciation and revenue growth, with a recent pullback from its all-time high. The stock trades at a premium valuation relative to sector peers, reflecting high growth expectations. Technicals show the stock is above key moving averages, and volatility remains elevated. Analyst targets suggest a broad range of possible outcomes, with the consensus leaning toward further upside, but caution is warranted due to the high valuation and recent profit stagnation
- As of the latest available data, Max Healthcare Institute Ltd (MAXHEALTH) is trading around ₹1,084.40, showing a 0.64% increase in the past 24 hours
- The stock hit a high of ₹1,095.00 and a low of ₹1,066.50 in the most recent trading session, with an average traded price of ₹1,075.13
- Over the past week, the stock is down by 0.97%, but it has risen 8.23% over the past month and 30.78% over the last year
**Historical Price Levels**
- MAXHEALTH reached its all-time high of ₹1,227.95 on January 8, 2025
- The all-time low was ₹97.15, recorded on November 12, 2020
**Analyst Forecasts and Valuation**
- Analyst price targets range from a minimum of ₹615.00 to a maximum of ₹1,390.00
- The stock is trading at a price-to-earnings (PE) ratio of 100.12 and a price-to-book (PB) ratio of 12.59, which is higher than the sector averages (sector PE: 47.87, sector PB: 6.12)
- Dividend yield is low at 0.14%
**Technical and Volatility Insights**
- MAXHEALTH is 2.61 times as volatile as the Nifty index, indicating higher price swings.
- The 50-day moving average (DMA) is at ₹1,062, suggesting the current price is above this technical support level.
MAXHEALTH's valuation is high compared to peers, reflecting strong investor expectations
**Fundamental Performance**
- Revenue has grown at a compound annual rate of 27.47% over the last five years, outpacing the industry average of 10.01%
- Net profit for FY 2023-24 was ₹687 crore, with a slight decline of 1.02% compared to the previous year, despite a 22.93% rise in revenue.
- Promoter and institutional holdings have remained stable in recent quarters
**Summary**
MAXHEALTH has demonstrated robust long-term price appreciation and revenue growth, with a recent pullback from its all-time high. The stock trades at a premium valuation relative to sector peers, reflecting high growth expectations. Technicals show the stock is above key moving averages, and volatility remains elevated. Analyst targets suggest a broad range of possible outcomes, with the consensus leaning toward further upside, but caution is warranted due to the high valuation and recent profit stagnation
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.